Oral versus intravenous vinorelbine: clinical safety profile

Bibliography

• BURSTEIN HJ, BUNNELL CA, WINER EP: New cytotoxic agents and schedules for advanced breast cancer.Semi]. Oncol (2001) 28 (4):344–458.
   Google Scholar
• •Review of new treatments in ABC.
   Google Scholar
• JONES L, HAWKINS N, WEST WOOD M, WRIGHT K, RICHARDSON G, RIEMSMA R: Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced anclior metastatic breast cancer. Health 7echnol. Assess. (2004) 8(5):1–143.
   Google Scholar
• •A thororough review of capecitabine activity.
   Google Scholar
• BENGTSON EM, RIGAS JR: New oral chemotherapeutic agents for lung cancer. Drugs (1999) 58\(Suppl. 3):57–69.
   Google Scholar
• •A review of oral drugs in lung cancer.
   Google Scholar
• LIU G, FRANSSEN E, FICHT LI, WARNER E: Patients preference for oral versus intravenous palliative chemotherapy. Clin. Oncol (1997) 15(1):110–115.
   Web of Science ®Google Scholar
• ••A patient's preference study for oraltherapy.
   Google Scholar
• GRALLA RJ, THATCHER N: Quality-of-life assessment in advanced lung cancer: considerations for evaluating patients receiving chemotherapy. Lung Cancer (2004) 46\(Suppl. 2):54l-547. QoL in lung cancer.
   Google Scholar
• ZHOU XJ, BORE P, MONJANEL S et al: Pharmacokinetics of navelbine after oral administration in cancer patients. Cancer Chemother. Pharmacol (1991) 29(1):66–70.
   PubMed Web of Science ®Google Scholar
• SAHNOUN Z, ZHOU XJ, BORE P et al: Clinical pharmacokinetics of navelbine after oral administration, in vitro metabolism and interindividual variability. Bull. Cancer (1990) 77(11):1115–1121.
   PubMed Web of Science ®Google Scholar
• RAHMANI R, ZHOU XJ, BORE P, VAN CANTFORT J, FOCAN C, CANO JP: Oral administration of [3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods. Anticancer Drugs (1991) 2(4):405–410.
   PubMed Web of Science ®Google Scholar
• LEVEQUE D, JEHL F: Determination of vinorelbine in biological fluids by high-performance liquid chromatography. I Chromatogr. B. Biorned. Appl. (1995) 34:672–314.
   Google Scholar
• MARQUET P, LACHATRE G, DEBORD J et al: Pharmacokinetics of vinorelbine in man. Eur. Clin. Pharmacol (1992) 42:545–547.
   Web of Science ®Google Scholar
• VAN TELLINGEN, KUIJPERS AV, BEIJNEN JH et al: Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography. Invest. New Drugs (1993) 11:141–150.
   PubMed Web of Science ®Google Scholar
• SCHILLING T, FIEBIG HH, KERPEL F et al: Clinical Phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients. Invest. New Drugs (1996) 14:371–378.
   PubMed Web of Science ®Google Scholar
• GAUVIN A, PINGUET F, POUJOL S: High-performance liquid chromatographic determination of vinorelbine in human plasma and blood: application to a pharmacokinetic study. I Chromatogr. B. Biorned. Li. Appl. (2000) 748:389–399.
   PubMed Web of Science ®Google Scholar
• PUOZZO C, UNG HL, ZORZA G: A high performance liquid chromatography method for vinorelbine and 4–0 deacetyl-vinorelbine: a decade of clinical routine analysis in blood, plasma and urine. Chromatogr. (2005) In press.
   Google Scholar
• VAN HEUGEN JC, DE GRAEVE J, ZORZA G, PUOZZO C: New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces.j Chromatogr. (2001) 926:11–20.
   Web of Science ®Google Scholar
• URIEN S, BREE F, BREILLOUT F et al: Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood. Cancer Chemother. Pharmacol (1993) 32:231–234.
   PubMed Web of Science ®Google Scholar
• BREE F, BLANCHOT G, TILLEMENT JP, VARIOL P, FAHY J, PUOZZO C: In vitro distribution of [31-]-vinflunine in human blood: binding to platelets and serum proteins. Proc. Am. Ass. Cancer Res. (2002) Abstract 1047.
   Google Scholar
• KHAYAT D, RIXE O, BRUNET et al: Pharmacokinetic linearity of IV vinorelbine from an intra-patient dose escalation study design. Cancer Chemother. Pharmacol (2004) 54(3):193–205.
   PubMed Web of Science ®Google Scholar
• PUOZZO C, ZORZA G, GUIMBAUD R et al: Metabolism of vinorelbine in human: clinical application. Proceedings Am. Ass. Cancer Res. (2000) CA41:280, Abstract 781.
   Google Scholar
• FOCAN C, KREUTZ F, LEROY I et al: Pharmacokinetics and mass-balance elimination of 3H-vinorelbine following IV and oral administration to patients. Proc. Am. Ass. Cancer Res. (2001) 42:383 (Abstract 2064).
   Google Scholar
• KAJITA J, KUWABARA T, KOBAYASHI H et al: CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab. Dispos. (2000) 28(9):1121–1127.
   PubMed Web of Science ®Google Scholar
• BEULZ-RICHE D, GRUDE P, PUOZZO C et al: Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundamental Clin. Pharmacol (2005) In press.
   Google Scholar
• SOUDON J, ZORZA G, VAN HEUGEN JC et al: Search for vinorelbine metabolite activity: an IP vitro cytotoxicity study using human ovary and lung cancer cell lines. Proc. Am. Ass. Cancer Res. (2001) 43:345 (Abstract 2909).
   Google Scholar
• MARTY M, FUMOLEAU P, ADENIS A et al: Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann. Oncol (2001) 12(11):1643–1649.
   PubMed Web of Science ®Google Scholar
• •Review of oral vinorelbine pharmacology.
   Google Scholar
• ROWINSKY EK, NOE DA, TRUMP DL et al.: Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J. CIin. Oncol (1994) 12(9):1754–1763.
   PubMed Web of Science ®Google Scholar
• WINER EP, CHU L, SPICER DV: Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. Semin. Oncol (1995) 22(2 Suppl. 5):72–78.
   Google Scholar
• VOKES EE, ROSENBERG R, JAHANZEB M et al.: Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report. Sem. Oncol (1994) 21(5 Suppl. 10):35–38.
   Google Scholar
• VARIOL P, PUOZZO C, CHEVALLIER B, FOCAN C et al: Pharmacokinetics of oral vinorelbine in women with advanced breast cancer. Proc. Am. Ass. Cancer Res. (1996) Abstract 1229.
   Google Scholar
• BONNETERRE J, CHEVALIER B, FOCAN C, MAURIAC L, PICCART M: Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). Ann. Oncol (2001) 12(12):1683–1691.
   PubMed Web of Science ®Google Scholar
• PUOZZO C, FUMOLEAU P, ADENIS A, ROUSSEAU F et al: Bioavailability and pharmacokinetics of oral vinorelbine in patients with solid tumors. Proc. Am. Ass. Cancer Res. AACR (1997) Abstract 4009.
   Google Scholar
• BOURGEOIS H, VERMORKEN J, DARK G et al.: Proven bio-equivalence of blood exposure between vinorelbine 80 mg/ m2 oral and 30 mg/m2 IV doses in cancer patients. Proceedings Am. Ass. Cancer Res. (2005) Abstract 2028.
   Google Scholar
• VARIOL P, ROCHE H, FUMOLEAU P et al: Effects of food on pharmacokinetic (PK) profile and safety of oral vinorelbine (VRL) in patients with solid tumors or lymphomas. Proc. Am. Soc. Clin. Oncol (1998) Abstract 849.
   Google Scholar
• BUGAT R, VARIOL P, ROCHE H, FUMOLEAU P, ROBINET G, SENCAC I: The effects of food on the pharmacokinetic profile of oral vinorelbine. Cancer Chemother. Pharmacol (2002) 50:285–290.
   PubMed Web of Science ®Google Scholar
• •Effects of food on oral vinorelbine PK.
   Google Scholar
• VARIOL P, NGUYEN L, TRANCHAND B, PUOZZO C: A simultaneous oral/i:v. population pharmacokinetic model for vinorelbine. Eur. I Clinic. Pharmacol (2002) 58:467–476.
   Google Scholar
• SHEINER LB, LUDDEN TM: Population pharmacokinetics/dynamics. Ann. Rev Pharmacol Toxicol (1992) 32:185–209.
   PubMed Web of Science ®Google Scholar
• PETRICOUL O, CLARET L, BARBOLOSI D, ILIADIS A, PUOZZO C: Information tools for exploratory data analysis in population pharmacokinetics. Pharmacokinetics Pharmacodynamics (2001) 28(6):577–599.
   PubMed Web of Science ®Google Scholar
• NGUYEN L, TRANCHANT B, PUOZZO C, VARIOL P: Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from Phase I clinical trials. BE J. Clin. Pharmacol (2002) 53:459–468.
   PubMed Web of Science ®Google Scholar
• DEPORTE-FETY R, SIMON N, FUMOLEAU P, CAMPONE M, KERBRAT P, BONNETERRE J et al.: Population pharmacokinetics of short intravenous vinorelbine infusion in patients with metastatic breast cancer. Cancer Chemother. Pharmacol a(2004) 53(3):233–238.
   PubMed Web of Science ®Google Scholar
• GAUVIN A, PINGUET F, CULINE S, ASTRE C, GOMENI R, BRESSOLLE F: Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin. Cancer Res. (2000) 6(7):2690–2695.
   PubMed Web of Science ®Google Scholar
• GAUVIN A, PINGUET F, CULINE S, ASTRE C, GOMENI R, BRESSOLLE F: A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. Anticancer Drugs (2002) 13(5):473–480.
   PubMed Web of Science ®Google Scholar
• SABOT C, MARQUET P, DEBORD J, CARPENTIER N, MERLE L, LACHATRE G: Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. Eur. Clin. Pharmacol (1998) 54(2):171–175.
   Web of Science ®Google Scholar
• PUOZZO C, GRIDELLI C: Non-small cell lung cancer in elderly patients: influence of age on Navelbine® oral pharmacokinetics. Clin. Lung Cancer (2004) 5(4):237–242.
   PubMedGoogle Scholar
• •Review of oral vinorelbine in elderly patiens with NSCLC.
   Google Scholar
• LE CHEVALIER T, BRISGAND D, DOUILLARD JY et al.: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients./. Clin. Oncol (1994) 12:360–367.
   Google Scholar
• DEPIERRE A, CHASTANG C, QUOIX E et al: Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann. Oncol (1994) 5:37–42.
   PubMed Web of Science ®Google Scholar
• GRIDELLI C, PERRONE F, GALLO C, et al: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter italian lung cancer in the elderly study (MILES). Phase III randomized trial. J. Nati Cancer Instit. (2003) 95(5):362–372.
   PubMed Web of Science ®Google Scholar
• KELLY K, CROWLEY J, BUNN PA Jr et al: Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J. Clin. Oncol. (2001) 19:3210–3218.
   PubMed Web of Science ®Google Scholar
• GEBBIA V, GALETTA D, RICCARDI F et al: Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin c in stage III-IV non-small cell lung carcinoma: a prospective randomized study. Lung Cancer (2002) 37:179–187.
   PubMed Web of Science ®Google Scholar
• GEBBIA V, GALETTA D, CARUSO M, VERDERAME F, PEZZELLA G, VALDESI M et al: Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide + gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized Phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer (2003) 39(2):179–189.
   PubMed Web of Science ®Google Scholar
• SCAGLIOTTI GV, DE MARINIS F, RINALDI M et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. Italian Lung Cancer Project. J. CM]. Oncol. (2002) 20:4285–4291.
   PubMed Web of Science ®Google Scholar
• THE INTERNATIONAL ADJUVANT LUNG CANCER TRIAL COLLABORATIVE GROUP: Cisplatin-based adjuvant Chemotherapy in patients with completely resected non-small-cell lung cancer. New Engl. J. Med. (2004) 340(4):351–360.
   Google Scholar
• ALAM N, SHERPERD FA, WINTON T et al.: Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer (2005) 47(3):385–394.
   Google Scholar
• ••Vinorelbine as adjuvantchemotherapy for NSCLC.
   Google Scholar
• VOKES EE, ROSENBERG RK, JAHANZEB M et al: Multicenter Phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. J. Clin. Oncol. (1995) 13 (3):637–644.
   PubMed Web of Science ®Google Scholar
• DEPIERRE A, FREYER G, JASSEM J et al: Oral vinorelbine: feasibility and safety profile. Ann. Oncol. (2001) 12(12):1677–1681. Review of safety and efficacy of oral vinorelbine.
   Google Scholar
• JASSEM J, RAMLAU R, KARNICKA-MLODKOWSKA H et al: A multicenter randomized Phase II study of oral versus intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann. Oncol. (2001) 12(10):1375–1381.
   PubMed Web of Science ®Google Scholar
• ••Direct comparison betweenoral and iv. vinorelbine.
   Google Scholar
• GEBBIA V, TESTA A, VALENZA R, CANNATA G, VERDERAME F, GEBBIA N: Acute pain syndrome at tumour site in neoplastic patients treated with vinorelbine: report of unusual toxicity. Eur. J. Cancer (1994) 30A(6):889.
   PubMed Web of Science ®Google Scholar
• DE PAST, SBANOTTO A, CATANIA C, BANFI MG, CURIGLIANO G, NOLE F et al.: Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. Support. Care Cancer (2005) 13(3):194–195.
   PubMed Web of Science ®Google Scholar
• FUMOLEAU P, DELGADO DM, DELOZIER T et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. Oncol. (1993) 11:1245–1252.
   Google Scholar
• GARCIA-CONDE J, LLUCH L, MARTIN M et al: Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann. Oncol. (1994) 5(9):854–857.
   PubMed Web of Science ®Google Scholar
• GARCIA-CONDE J, LLUCH A, MARTIN M et al: Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann.Onco. (1994) 5:854–857.
   PubMed Web of Science ®Google Scholar
• QUEISSER W, DOSS A, WANDER HE et al.: Phase II study of vinorelbine by oral route (in a hard gelatin capsule) for metastatic breast cancer patients. A trial of the Phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onko/ogie (1991) 14(1):35–39.
   Google Scholar
• WINER E, CHU L, SPICER DV: Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. Semi]. Oncol. (1995) 22(2 Suppl. 5):72–78.
   Google Scholar
• FREYER G, DELOZIER T, LICHINISTER M et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. Oncol. (2003) 21(1):35–40. Activity and safety of oral vinorelbine in ABC.
   Google Scholar
• AMADORI D, KORALEWSKI P, TEKIELA A: Efficacy and safety of navelbine oral (NVBO) in first line metastatic breast cancer (MBC). Eur. J. Cancer (2001) 37:22 Abstract.
   Google Scholar
• BARTSCH R, PLUSCHNIG U, WENZEL C et al.: Oral vinorelbine in the treatment of advanced breast cancer. Proc. Am. Soc.Clin. Oncol. I Clin. Oncol. (2004) 22 (145):33s Abstract 626.
   Google Scholar
• BALDUCCI L, EXTERMANN M: Management of the frail person with advanced cancer. Grit. Rev Oncol. Hematol. (2000) 33:143–148.
   PubMed Web of Science ®Google Scholar
• MALIK SM: The impact of aging on chemotherapy. Clin. Lung Cancer (2004) 5:243–244.
   PubMedGoogle Scholar
• PUOZZO C, GRIDELLI C, JAWORSKY M: Pharmacokinetics of Navelbine oral in elderly patients. Tumori (2002) 88(1 Suppl. 1):575–576.
   Google Scholar
• GRIDELLI C, MANEGOLD C, MALI P et al: Oral vinorelbine give as monochemotherapy to advanced, elderly NSCLC patients: a multicenter Phase II study. Eur. J. Cancer (2004) 40:2424–2431.
   PubMed Web of Science ®Google Scholar
• •Oral vinorelbine in elderly patiens with NSCLC.
   Google Scholar
• KANARD A, JATOI A, CASTILLO R et al: Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a Phase II trial of efficacy and toxicity. Lung Cancer (2004) 43(3):345–53.
   PubMed Web of Science ®Google Scholar
• VOGEL C, O'ROURKE M, WINER E etal: Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann. Oncol. (1999) 10(14):397–402.
   PubMedGoogle Scholar
• BRAUD AC, JOLY F, RIOS M et al: Preservation of activities daily living (ADL) in a Phase II impact study of oral capecitabine and vinorelbine in the treatment of metastatic carcinomas in patients older than 70 years: the GERICO-01 study by the French FNCLCC group. Proc. Am. Soc. Clin. Oncol. (2004) 22(14):768s Abstract 8160.
   Google Scholar
• JASSEM J, KOSMIDIS P, RAMLAU R et al: Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann. Oncol. (2003) 14(11):1634–1639.
   PubMed Web of Science ®Google Scholar
• •Activity of oral vinorelbine plus cisplatin in NSCLC.
   Google Scholar
• DE LENA MD, RAMLAU R, HANSEN O et al: Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lung Cancer (2005) 48:129–135.
   PubMed Web of Science ®Google Scholar
• ••Role of oral vinorelbinein advanced NSCLC.
   Google Scholar
• GEBBIA V, GALETTA D, CARUSO M et al.: Phase III trial comparino cisplatin (CDDP) plus weekly vinorelbine (VNR) to CDDP and day 1+8 VNR in advanced non-small cell lung cancer (NSCLC). Lung Cancer (2003) 41 (Suppl. 2):216 Abstract.
   Google Scholar
• O'BRIEN ME, SZCZESNA A, KARNICKA H, ZATLOUKAL P, EISEN T, HARTMANN W et al: Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre Phase II study. Ann. Oncol (2004) 15(6):921–927.
   PubMed Web of Science ®Google Scholar
• AHN JH, KIM SB, KIM TW M et al: Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J. Korean Med. ScL (2004) 19(4):547–553.
   PubMed Web of Science ®Google Scholar